Streetbeat News

Price Targets

CNMD

Needham analyst Mike Matson maintains a Buy rating on Conmed (NYSE:CNMD) and raises the price target from $119 to $129.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:22 pm

MXL

Needham analyst Quinn Bolton maintains a Buy rating on MaxLinear (NASDAQ:MXL) but lowers the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:10 pm

QRVO

Needham analyst Quinn Bolton has reiterated a Buy rating on Qorvo (NASDAQ:QRVO) and maintained a $125 price target.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:09 pm

MAMA

Roth MKM analyst George Kelly initiates coverage on Mama's Creations (NASDAQ:MAMA) with a Buy rating and a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:05 pm

ARVN

Goldman Sachs analyst Paul Choi has initiated coverage on Arvinas (NASDAQ:ARVN) with a Buy rating and set a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:04 pm

BSX

Boston Scientific (NYSE:BSX) has received diverse analyst ratings over the last three months, with a total of 10 analysts offering perspectives ranging from bullish to bearish. The recent ratings show an increase in bullish sentiment, with an average 12-month price target set at $64.9, marking a 7.97% increase from the previous average of $60.11. Analysts from firms like Needham, RBC Capital, and Raymond James have adjusted their ratings and price targets, reflecting optimism about the company's future performance. Boston Scientific is known for producing less invasive medical devices, with foreign sales making up nearly half of its total sales. Despite its strong market position and revenue growth, the company faces challenges in ROE and ROA, indicating potential difficulties in efficiently utilizing equity capital and assets.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 12:01 pm

GWRE

Guidewire Software (NYSE:GWRE) has received diverse analyst ratings ranging from bullish to bearish, with a recent shift towards more positive evaluations. Six analysts have updated their ratings, leading to an increased average 12-month price target of $113.67, up 15.05% from the previous target. The company's financial performance shows a positive revenue trend but struggles with profitability and return metrics. Guidewire Software offers software solutions for property and casualty insurers, with a market capitalization below industry averages.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 12:01 pm

LII

Analysts have provided diverse opinions on Lennox Intl (LII) with a recent shift towards bullish ratings. The average 12-month price target has been raised to $494.8, indicating a 20.19% increase from the previous target. Lennox Intl's financial performance shows strong revenue growth and ROE, but challenges in net margin and debt management. The company focuses on HVAC and refrigeration products, primarily in North America.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 12:00 pm

DVAX

Goldman Sachs analyst Paul Choi has initiated coverage on Dynavax Technologies (DVAX) with a Neutral rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:00 pm

BG

Bunge Global (NYSE:BG) received mixed analyst ratings with a shift towards a more cautious outlook, as evidenced by lowered price targets and a decrease in the average 12-month price target from $136.67 to $118. Analysts from Citigroup, Goldman Sachs, Baird, and Barclays adjusted their ratings and price targets, reflecting changes in market conditions and Bunge Global's performance. Despite a revenue decline of -15.11% over the past 3 months, Bunge Global maintains strong profitability indicators such as a net margin of 2.62%, ROE of 3.58%, and ROA of 1.47%, with a conservative debt-to-equity ratio of 0.58.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 12:00 pm